Edition:
United States

Genmab A/S (GEN.CO)

GEN.CO on Copenhagen Stock Exchange

1,227.00DKK
23 May 2018
Change (% chg)

kr.-5.50 (-0.45%)
Prev Close
kr.1,232.50
Open
kr.1,231.00
Day's High
kr.1,239.00
Day's Low
kr.1,217.50
Volume
166,667
Avg. Vol
245,148
52-wk High
kr.1,486.00
52-wk Low
kr.994.80

Select another date:

Tue, Apr 17 2018

BRIEF-Genmab: Q1 Net Sales Of Darzalex At $432 Mln

* REG-GENMAB ANNOUNCES NET SALES OF DARZALEX® (DARATUMUMAB) FOR FIRST QUARTER OF 2018

Biotech group Genmab aims to own bigger share of new drug pipeline

COPENHAGEN, April 10 Genmab plans to own a bigger share of drugs in its early-stage pipeline as Europe's biggest biotechnology company prepares to reduce its reliance on a blockbuster cancer drug, marketed by partner Johnson & Johnson.

BRIEF-Genmab ‍2017 Operating Profit Beats Expectations

* ‍PROJECTED REVENUE FOR 2018 CONSISTS PRIMARILY OF DARZALEX ROYALTIES OF APPROXIMATELY DKK 1,750 MLN THAT ARE BASED ON AN ESTIMATED USD 2.0 - 2.3 BLN OF DARZALEX NET SALES IN 2018​

BRIEF-Genmab 2017 Net Sales Of DARZALEX At $1.24 Billion

* ANNOUNCES 2017 NET SALES FIGURES FOR DARZALEX® (DARATUMUMAB)

BRIEF-Genmab Gets USD 50 Mln From Novartis For Lost Potential Milestones And Royalties​

* ANNOUNCES NOVARTIS’ INTENTION TO TRANSITION ARZERRA® (OFATUMUMAB) FROM COMMERCIAL AVAILABILITY TO LIMITED AVAILABILITY VIA COMPASSIONATE USE PROGRAMS FOR THE TREATMENT OF CLL IN NON-US MARKETS

BRIEF-U.S. FDA Grants Priority Review For Daratumumab In Front Line Multiple Myeloma

* U.S. FDA GRANTS PRIORITY REVIEW FOR DARATUMUMAB IN FRONT LINE MULTIPLE MYELOMA

BRIEF-Gemnab Says Artisan Partners Increased Indirect Ownership In Co To 5.04 Pct Of Share Capital and Voting Rights

* GENMAB - ‍ARTISAN PARTNERS INCREASED THEIR INDIRECT OWNERSHIP IN CO TO 3,081,731 SHARES, AMOUNTING TO 5.04% OF SHARE CAPITAL, VOTING RIGHTS IN CO

BRIEF-Biotech Genmab sees 2018 expense growth of 40-50 pct

Dec 12 FOLLOWING ARE STATEMENTS FROM GENMAB'S R'N'D UPDATE IN ATLANTA, GEORGIA:

Genmab and Johnson & Johnson 'love' partnership as some ponder takeover

LONDON Genmab was Europe's second biggest biotech company, until its partner Johnson & Johnson bought Switzerland's Actelion for $30 billion this year and propelled the Danish antibody specialist to the top spot.

Europe's top biotech expects delays from drugs watchdog's HQ move

LONDON Europe's biggest biotechnology company, Denmark's Genmab, expects some delays to regional drug approvals as the European Medicines Agency is uprooted from London to Amsterdam.

Select another date: